{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:04:37Z","timestamp":1791230677826,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s40265-014-0200-1","type":"journal-article","created":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T07:00:58Z","timestamp":1394175658000},"page":"505-511","source":"Crossref","is-referenced-by-count":41,"title":["Tasimelteon: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,8]]},"reference":[{"issue":"5","key":"200_CR1","first-page":"345","volume":"19","author":"GM Brown","year":"1994","unstructured":"Brown GM. Light, melatonin and the sleep\u2013wake cycle. J Psychiatry Neurosci. 1994;19(5):345\u201353.","journal-title":"J Psychiatry Neurosci"},{"issue":"4","key":"200_CR2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jsmc.2010.08.001","volume":"5","author":"ER Dodson","year":"2010","unstructured":"Dodson ER, Zee PC. Therapeutics for circadian rhythm sleep disorders. Sleep Med Clin. 2010;5(4):701\u201315.","journal-title":"Sleep Med Clin"},{"issue":"1","key":"200_CR3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/074873049701200104","volume":"12","author":"SW Lockley","year":"1997","unstructured":"Lockley SW, Skene DJ, Tabandeh H, et al. Relationship between napping and melatonin in the blind. J Biol Rhythms. 1997;12(1):16\u201325.","journal-title":"J Biol Rhythms"},{"issue":"4","key":"200_CR4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1192\/bjp.bp.108.050955","volume":"193","author":"J Arendt","year":"2008","unstructured":"Arendt J, Rajaratnam SMW. Melatonin and its agonists: an update. Br J Psychiatry. 2008;193(4):267\u20139.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"200_CR5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/187152412802430129","volume":"12","author":"R Hardeland","year":"2012","unstructured":"Hardeland R, Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem. 2012;12(3):189\u2013216.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"200_CR6","unstructured":"Takeda Pharmaceuticals. Rozeram (ramelteon): US prescribing information. 2010. http:\/\/www.rozerem.com\/en\/?#. Accessed 27 Feb 2014."},{"issue":"4","key":"200_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-079X.2011.00962.x","volume":"52","author":"DP Cardinali","year":"2012","unstructured":"Cardinali DP, Srinivasan V, Brzezinski A, et al. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365\u201375.","journal-title":"J Pineal Res"},{"key":"200_CR8","unstructured":"Vanda Pharmaceuticals Inc. FDA approves HETLIOZTM (tasimelteon) for the treatment of non-24-hour sleep\u2013wake disorder [media release]. 31 Jan 2014. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1895838&highlight= ."},{"key":"200_CR9","unstructured":"Vanda Pharmaceuticals Inc. Hetlioz (tasimelteon): US prescribing information. 2014. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205677s000lbledt.pdf . Accessed 14 Feb 2014."},{"key":"200_CR10","unstructured":"Vanda Pharmaceuticals Inc. Vanda announces submission to FDA of a new drug application for tasimelteon for the treatment of non-24-hour disorder in the totally blind [media release]. 31 May 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1825812&highlight= ."},{"key":"200_CR11","unstructured":"Vanda Pharmaceuticals Inc. FDA accepts tasimelteon new drug application for priority review in the treatment of non-24-hour disorder in the totally blind [media release]. 29 Jul 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1842208&highlight= ."},{"key":"200_CR12","unstructured":"Vanda Pharmaceuticals Inc. FDA advisory committee recommends approval of HETLIOZTM for the treatment of non-24-hour-disorder (non-24) in the totally blind [media release]. 14 Nov 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1877276&highlight= ."},{"key":"200_CR13","unstructured":"Vanda Pharmaceuticals Inc. Vanda reports successful completion of pre-NDA meeting with FDA on tasimelteon for the treatment of non-24-hour disorder in the totally blind [media release]. 25 Mar 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1799843&highlight= ."},{"key":"200_CR14","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals reports fourth quarter and full year 2009 results [media release]. 16 Feb 2010. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1391121&highlight= ."},{"key":"200_CR15","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals receives orphan drug designation in Europe for tasimelteon [media release]. 8 Mar 2011. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1536754&highlight= ."},{"key":"200_CR16","unstructured":"Vanda Pharmaceuticals Inc. Phase III data show Vanda Pharmaceuticals\u2019 tasimelteon (VEC-162) significantly improves sleep in patients with chronic insomnia [media release]. 26 Jun 2008. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1169632&highlight= ."},{"key":"200_CR17","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals reports fourth quarter and full year 2006 results [media release]. 7 Feb 2007. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=959701&highlight= ."},{"key":"200_CR18","first-page":"A43","volume":"32 Suppl","author":"J Feeney","year":"2009","unstructured":"Feeney J, Birznieks G, Scott C, et al. Melatonin agonist tasimelteon improves sleep in primary insomnia characterized by difficulty falling asleep [abstract no. 0127]. Sleep. 2009;32 Suppl:A43.","journal-title":"Sleep"},{"key":"200_CR19","unstructured":"Vanda Pharmaceuticals Inc. Vanda announces phase IIb\/III clinical study in major depressive disorder did not meet the primary endpoint [media release]. 31 Jan 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1779830&highlight= ."},{"key":"200_CR20","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals reports first quarter 2013 results [media release]. 9 May 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1817533&highlight= ."},{"key":"200_CR21","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals Inc. prices public offering of common stock [media release]. 7 Aug 2013. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=196233&p=irol-newsArticle&ID=1845585&highlight= ."},{"key":"200_CR22","unstructured":"Vanda Pharmaceuticals. Pharmacokinetics of tasimelteon alone and in combination with a CYP3A4 inhibitor, ketoconazole, or a CYP3A4 inducer, rifampin [ClinicalTrials.gov identifier NCT01637636] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/show\/NCT01637636 . Accessed 18 Feb 2014."},{"key":"200_CR23","unstructured":"Vanda Pharmaceuticals. Pharmacokinetics of tasimelteon alone and in combination with CYP1A2 inhibitor, fluvoxamine [ClinicalTrials.gov identifier NCT01540500] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01540500?term=NCT01540500&rank=1 . Accessed 18 Feb 2014."},{"key":"200_CR24","unstructured":"Vanda Pharmaceuticals. Pharmacokinetics of tasimelteon in subjects with renal impairment and matched control subjects with relatively normal renal function [ClinicalTrials.gov identifier NCT01526746] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01526746?term=NCT01526746&rank=1 . Accessed 18 Feb 2014."},{"key":"200_CR25","unstructured":"Vanda Pharmaceuticals. Evaluation of the pharmacodynamic and pharmacokinetic interactions of tasimelteon and ethanol [ClinicalTrials.gov identifier NCT01578057] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01578057?term=NCT01578057&rank=1 . Accessed 18 Feb 2014."},{"key":"200_CR26","unstructured":"Vanda Pharmaceuticals. Effects of smoking, age and body size on pharmacokinetics, safety and tolerability on tasimelteon in healthy subjects [ClinicalTrials.gov identifier NCT01477619] US National Institutes of Health, ClinicalTrials.gov. 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01477619?term=NCT01477619&rank=1 . Accessed 18 Feb 2014."},{"key":"200_CR27","unstructured":"Vanda Pharmaceuticals. A study to assess the effect tasimelteon on the cytochrome P450 3A4 and 2C8 enzymes in healthy subjects [ClinicalTrials.gov identifier NCT01402076] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01402076?term=NCT01402076&rank=1 . Accessed 18 Feb 2014."},{"key":"200_CR28","unstructured":"Vanda Pharmaceuticals. Pharmacokinetics of tasimelteon in subjects with mild or moderate hepatic impairment [ClinicalTrials.gov identifier NCT01271387] US National Institutes of Health, ClinicalTrials.gov. 2014. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01271387?term=NCT01271387&rank=1 . Accessed 18 Feb 2014."},{"issue":"4","key":"200_CR29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/jps.10348","volume":"92","author":"NN Vachharajani","year":"2003","unstructured":"Vachharajani NN, Yeleswaram K, Boulton DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci. 2003;92(4):760\u201372.","journal-title":"J Pharm Sci"},{"key":"200_CR30","doi-asserted-by":"crossref","unstructured":"Lockley SW, Dressman MA, Xiao C, et al. Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefit in totally blind individuals with non-24-hour circadian rhythms [abstract no. FP26-6]. 95th Annual Meeting of the Endocrine Society; 15\u201318 Jun 2013; San Fransisco, CA.","DOI":"10.1016\/j.sleep.2013.11.417"},{"key":"200_CR31","unstructured":"Lockley SW, Dressman MA, Xiao C. RESET study demonstrates that tasimelteon maintains entrainment of melatonin and cortisol in totally blind individuals with non-24-hour circadian rhythms [abstract no. SUN-137]. 95th Annual Meeting of the Endocrine Society; 15\u201318 Jun 2013; San Fransisco, CA."},{"issue":"9662","key":"200_CR32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(08)61812-7","volume":"373","author":"SM Rajaratnam","year":"2009","unstructured":"Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials [erratum appears in Lancet. 2009;373(9671):1252]. Lancet. 2009;373(9662):482\u201391.","journal-title":"Lancet"},{"key":"200_CR33","first-page":"66","volume":"19 Suppl 2","author":"SMW Rajaratnam","year":"2010","unstructured":"Rajaratnam SMW. Melatonin and the melatonin receptor agonist tasimelteon for crcadian rhythm sleep disorders: understanding inter-individual differences in efficacy [abstract no. S238]. J Sleep Res. 2010;19 Suppl 2:66\u20137.","journal-title":"J Sleep Res"},{"key":"200_CR34","first-page":"A284","volume":"32 Suppl","author":"S Mitkus","year":"2009","unstructured":"Mitkus S, Birznieks G, Thompson A, et al. Effect of a PERIOD 3 (PER3) gene polymorphism on response to tasimelteon treatment in a phase advance model of transient insomnia. Sleep. 2009;32 Suppl:A284.","journal-title":"Sleep"},{"key":"200_CR35","unstructured":"Vanda Pharmaceuticals. Tasimelteon for the treatment of non-24-hour sleep\u2013wake disorder (N24HSWD) in blind individuals with no light perception [ClinicalTrials.gov identifier NCT01429116] US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01429116?show_locs=Y#locn . Accessed 18 Feb 2014."},{"key":"200_CR36","unstructured":"Vanda Pharmaceuticals. Safety study of tasimelteon for treatment of non-24-hour-sleep\u2013wake disorder in blind individuals with no light perception [ClinicalTrials.gov identifier NCT01218789] US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01218789?term=NCT01218789&rank=1 . Accessed 18 Feb 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0200-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0200-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0200-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T02:40:45Z","timestamp":1565232045000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0200-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0200-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}